Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study.
Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study.
复制标题
DOI：
10.1001/archophthalmol.2009.18
复制
发表时间：
2009-04
影响因子：
--
通讯作者：
Dana, Reza
中科院分区：
文献类型：
--
作者：
Dastjerdi, Mohammad H.;Al-Arfaj, Khalid M.;Nallasamy, Nambi;Hamrah, Pedram;Jurkunas, Ula V.;Pineda, Roberto, II;Pavan-Langston, Deborah;Dana, Reza
研究局部贝伐单抗治疗角膜新生血管（NV）的安全性和有效性。在一项前瞻性、开放标签、非比较研究中，10 名稳定角膜 NV 患者的 10 只眼睛接受了局部贝伐单抗 1.0% 治疗 3 周，并随访 24 周。主要安全性变量是整个研究过程中眼部和全身不良事件的发生率。主要功效变量是新生血管面积（NA），测量角膜血管本身的面积；血管口径（VC），测量角膜血管的平均直径；和侵袭面积（IA），测量血管覆盖的角膜总面积的比例。从基线访视到最后一次随访，NA 平均降低 47.1% ± 36.7%，VC 平均降低 54.1% ± 28.1，IA 平均降低 12.2% ± 42.0%。 NA 和 VC 的下降具有统计学意义（分别为 p = 0.0014 和 p = 0.00009）。然而，IA 的变化并未达到统计学显着性（p = 0.19）。视力和中央角膜厚度没有显着变化。局部贝伐珠单抗耐受性良好，无不良事件。短期局部贝伐单抗治疗可降低角膜 NV 的严重程度，且不会产生局部或全身副作用。局部贝伐珠单抗为治疗稳定的角膜新生血管提供了一种替代疗法。 ClinicalTrials.gov 标识符：NCT00559936
To study the safety and efficacy of topical bevacizumab in the treatment of corneal neovascularization (NV). In a prospective, open-label, non-comparative study, 10 eyes from 10 patients with stable corneal NV were treated with topical bevacizumab 1.0% for 3 weeks and followed up to 24 weeks. The primary safety variables were the occurrence of ocular and systemic adverse events throughout the course of the study. The primary efficacy variables were neovascular area (NA), measuring the area of the corneal vessels themselves; vessel caliber (VC), measuring the mean diameter of the corneal vessels; and invasion area (IA), measuring the fraction of the total corneal area covered by the vessels. From baseline visit to the last follow-up visit, the mean reduction was 47.1% ± 36.7% for NA, 54.1% ± 28.1 for VC, and 12.2% ± 42.0% for IA. The decreases in NA and VC were statistically significant (p = 0.0014 and p = 0.00009, respectively). However, changes in IA did not achieve statistical significance (p = 0.19). Visual acuity and central corneal thickness showed no significant changes. Topical bevacizumab was well-tolerated with no adverse events. Short-term topical bevacizumab therapy reduces the severity of corneal NV without local or systemic side-effects. Topical bevacizumab provides an alternative therapy in the treatment of stable corneal neovascularization. clinicaltrials.gov Identifier: NCT00559936
登录
查看更多内容
影响因子：
2.8
作者：
Cursiefen, C;Kuchle, M;Naumann, GOH
通讯作者：
Naumann, GOH
影响因子：
13.7
作者：
Kim, Sang Woo;Ha, Byung Jin;Kim, Tae-im
通讯作者：
Kim, Tae-im
影响因子：
4.4
作者：
Cursiefen, C;Cao, JT;Streilein, JW
通讯作者：
Streilein, JW
影响因子：
--
作者：
LIESEGANG, TJ
通讯作者：
LIESEGANG, TJ
影响因子：
4.1
作者：
Manzano, Roberta P. A.;Peyman, Gholam A.;Chevez-Barrios, Patricia
通讯作者：
Chevez-Barrios, Patricia